A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.

A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. Am J Cardiol. 2017 Aug 15; 120(4):569-576.

View in: PubMed

subject areas

Aged
Anticholesteremic Agents
Cholesterol, HDL
Dose-Response Relationship, Drug
Double-Blind Method
Drug Therapy, Combination
Drug Tolerance
Female
Follow-Up Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypercholesterolemia
Male
Middle Aged
Oxazolidinones
Time Factors
Treatment Outcome

authors with profiles

CHRISTIE BALLANTYNE